期刊
JOURNAL OF NUCLEAR MEDICINE
卷 54, 期 6, 页码 887-893出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.112.112599
关键词
dementia; Alzheimer disease; Lewy body dementia; frontotemporal dementia
资金
- PHS [P01 NS15655, P30 AG08671]
- NIH
- Department of Veteran's Affairs
- VA advanced fellowship
- Robert Wood Johnson Clinical Scholars Program
- NINDS (NIH)
- USPHS NIH
- GE Healthcare
- AVID Radiopharma
We evaluated PET-based classification of neurodegenerative pathology in mild cognitive impairment (MCI). Methods: Our study was a cross-sectional and prospective evaluation of a cohort of 27 MCI subjects drawn from a university-based cognitive disorders clinic. We compared expert clinical consensus classification of MCI at entry and possible dementia at follow-up with molecular imaging-based classification using C-11-dihydotetrabenazine PET measurement of striatal dopamine terminal integrity and C-11-Pittsburgh compound B (C-11-PiB) PET measurement of cerebral amyloid burden. Results: Eleven subjects were initially classified clinically as amnestic MCI, 7 as multidomain MCI, and 9 as nonamnestic MCI. At a mean follow-up of 3 y, 18 subjects converted to dementia. PET imaging evidence of significant cerebral amyloid deposition or nigrostriatal denervation was a strong predictor of conversion to dementia. There was only moderate concordance between expert clinical classifications and PET-based classifications of dementia subtypes. Conclusion: Combined PET molecular imaging of cerebral amyloid burden and striatal dopamine terminal integrity may be useful for identifying subjects at high risk for progression to dementia and in defining neurochemically differentiated subsets of MCI subjects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据